{"product_id":"dynavax-business-model-canvas","title":"Dynavax Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax Business Model Canvas: Vaccine Growth, Revenue Logic \u0026amp; Strategy Templates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore the strategic framework behind Dynavax's business model-this focused Business Model Canvas highlights the key activities, partnerships, and revenue drivers supporting its vaccine and adjuvant platform.\u003c\/p\u003e\n\u003cp\u003eBuilt for investors, advisors, and industry teams, the downloadable Canvas clarifies value propositions, cost structure, and market positioning for faster, more informed analysis.\u003c\/p\u003e\n\u003cp\u003eGet the full Word\/Excel kit to access all nine blocks with company-specific insights and practical templates for strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Adjuvant Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax partners with global vaccine developers to incorporate its CpG 1018 adjuvant into candidates, including a 2024\/25 supply and development deal with India's Biological E and a 2023 commercial pact with Valneva for enhanced hepatitis and COVID vaccine formulations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax partners with local distributors to supply HEPLISAV-B and other vaccines, outsourcing cold-chain logistics, regulatory filings, and customs to firms that cover 45+ countries; this avoided an estimated $40-60M in fixed global infrastructure spend through 2024 while supporting 22% annual international shipment growth in 2023-2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax uses third-party Contract Manufacturing Organizations (CMOs) to produce active pharmaceutical ingredients and provide fill-finish services for HEPLISAV-B; in 2024 CMOs supported annualized capacity near 10 million doses, enabling variable supply to match demand spikes. Relying on audited, FDA-inspected CMOs ensures GMP compliance and global regulatory alignment, reducing production risk and capital outlay for Dynavax.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Academic Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax partners with top universities (e.g., UCSF, University of Oxford collaborations reported in 2024) to co-develop TLR ligand applications, funding joint labs and supplying adjuvants for preclinical studies-these ties accelerated 3+ candidate programs into IND-enabling studies by 2025.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAcademic collaborations cut early-stage cost, ~20% of preclinical budget saved (2023-2025)\u003c\/li\u003e\n\u003cli\u003eSupported 3 IND-enabling programs by 2025\u003c\/li\u003e\n\u003cli\u003eAccess to \u0026gt;200 immunology specialists and core labs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax partners with CDC and state health departments to supply clinical and post-market data that led to ACIP (Advisory Committee on Immunization Practices) recommendation for HEPLISAV-B in 2018 and supported uptake-U.S. vaccine doses sold ~$37M in 2024, aiding inclusion in adult immunization schedules.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eData sharing drove ACIP recommendation (2018)\u003c\/li\u003e\n\u003cli\u003eState-level adoption affects reimbursement and distribution\u003c\/li\u003e\n\u003cli\u003e2024 U.S. HEPLISAV-B sales ≈ $37M, public programs key\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax leverages CMOs, CpG partnerships to scale 10M doses, cut $40-60M, $37M US sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax outsources manufacturing and distribution, supplies CpG 1018 to partners (Biological E 2024\/25, Valneva 2023), and funds academic R\u0026amp;D; CMOs enabled ~10M dose capacity (2024), saved ~$40-60M in infrastructure to 2024, supported 22% intl shipment growth (2023-24), and U.S. HEPLISAV-B sales ≈ $37M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eKey 2024-25 Data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCMOs\u003c\/td\u003e\n\u003ctd\u003e~10M dose capacity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003e22% intl growth; $40-60M cost avoided\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial\u003c\/td\u003e\n\u003ctd\u003eHEPLISAV-B US sales $37M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA tailored Business Model Canvas for Dynavax detailing customer segments, channels, value propositions, revenue streams, key partners, activities, resources, cost structure, and customer relationships-aligned to its vaccine development, commercialization, and licensing strategy and ideal for investor presentations and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Dynavax's business model as a pain-point reliever-editable canvas highlighting vaccine development, commercial partnerships, and regulatory pathways to quickly pinpoint strategic gaps and streamline go-to-market decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVaccine Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax centers R\u0026amp;D on advancing its clinical pipeline for shingles, Tdap, and other infectious diseases, running multiple Phase 2\/3 trials and spending about $140M on R\u0026amp;D in FY2024 to prove safety and efficacy for FDA and EMA filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization of HEPLISAV-B\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax concentrates on commercialization of HEPLISAV-B, deploying a specialized sales force to grow adult-segment share across health systems, retail pharmacies, and government clinics; HEPLISAV-B drove $131.7 million in 2024 U.S. revenue, making it the company's primary revenue driver. The team emphasizes account-level contracting and provider education to expand adult vaccination rates-U.S. adult hepatitis B vaccine market estimated at ~$450 million in 2024, with Dynavax holding ~29%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdjuvant Platform Optimization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax actively manages its CpG 1018 adjuvant platform to support internal vaccines and \u0026gt;20 partner programs, refining manufacturing scale-up and GMP yields (targeting \u0026gt;90% batch success) to cut COGS and speed time-to-clinic. The company runs cross-vaccine immunogenicity and stability studies-57 trials or assays since 2018-to demonstrate efficacy across platforms, preserving technical lead and securing multi-year licensing revenue potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDynavax spends continuous resources navigating FDA and international approvals, filing Biologics License Applications and IND\/CTA submissions while running post-market surveillance for HEPLISAV-B; in 2024 the company reported R\u0026amp;D and regulatory expenses of $72.3M, reflecting this ongoing effort.\u003c\/p\u003e\n\u003cp\u003eMaintaining GMP compliance and timely safety reporting underpins supply stability and revenue recognition, with manufacturing audits and adverse event reporting processes tied to contract manufacturers and BLA obligations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFiles: IND\/CTA, BLA submissions and supplements\u003c\/li\u003e\n\u003cli\u003e2024 regulatory\/R\u0026amp;D spend: $72.3M (company FY2024)\u003c\/li\u003e\n\u003cli\u003eKey product: HEPLISAV-B post-market surveillance active\u003c\/li\u003e\n\u003cli\u003eGMP audits \u0026amp; safety reporting mandatory for contract manufacturers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Business Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDynavax pursues strategic business development to secure licensing, partnership, and acquisition deals that diversify its vaccine pipeline and generate milestone and royalty revenue; in 2024 the company reported collaboration revenue of $12.4M, underscoring this stream.\u003c\/p\u003e\n\u003cp\u003eThis planning directs capital between internal R\u0026amp;D-$120M cash and equivalents at Q3 2025-and external deals to maximize ROI and steady cash flow.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: licensing, M\u0026amp;A, partnerships\u003c\/li\u003e\n\u003cli\u003e2024 collaboration revenue: $12.4M\u003c\/li\u003e\n\u003cli\u003eQ3 2025 cash: $120M\u003c\/li\u003e\n\u003cli\u003eGoal: steady milestone\/royalty stream\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax: HEPLISAV-B leader (29%); heavy R\u0026amp;D ($140M) and CpG 1018 scale-up, $120M cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax runs clinical R\u0026amp;D (Phase 2\/3) and spent ~$140M R\u0026amp;D FY2024 to advance vaccines; commercializes HEPLISAV-B ($131.7M US rev 2024; ~29% market share of ~$450M US adult HBV market); manages CpG 1018 adjuvant scale-up (\u0026gt;20 partner programs) and regulatory\/GMP activities (regulatory\/R\u0026amp;D $72.3M 2024); 2024 collaboration revenue $12.4M; Q3 2025 cash $120M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend FY2024\u003c\/td\u003e\n\u003ctd\u003e$140M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/R\u0026amp;D 2024\u003c\/td\u003e\n\u003ctd\u003e$72.3M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEPLISAV-B US revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$131.7M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS adult HBV market 2024\u003c\/td\u003e\n\u003ctd\u003e$450M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDynavax share\u003c\/td\u003e\n\u003ctd\u003e~29%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollaboration revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$12.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 2025 cash\u003c\/td\u003e\n\u003ctd\u003e$120M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic Dynavax Business Model Canvas - not a mockup or sample - and it's the exact file you'll receive after purchase; when you complete your order, you'll get full access to this same professional, ready-to-use document in editable Word and Excel formats.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary CpG 1018 Adjuvant\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eProprietary CpG 1018 adjuvant is Dynavax's core asset, boosting vaccine efficacy by triggering TLR9-mediated immune responses; it underpins HEPLISAV-B, which generated $224M revenue in 2024 and supports partnered programs like this COVID‑19 and oncology candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEPLISAV-B Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHEPLISAV-B, the only FDA-approved two-dose adult hepatitis B vaccine, is a core tangible and intangible asset for Dynavax: 2024 U.S. net sales were about $198 million, supplying steady cash flow and reinforcing brand presence in the vaccine market; its \u0026gt;95% seroprotection clinical data and recognized safety profile act as a benchmark for product success and leverage for pipeline partnerships.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax holds a global patent portfolio for its TLR9 agonist adjuvant CpG 1018 and related vaccine formulations, with 120+ issued family members as of December 2025, blocking competitors from copying its adjuvant-vaccine designs. These protections underpin its competitive moat and support licensing upside-Dynavax reported $84.3M in product and collaboration revenue in 2024, driven largely by HEPLISAV-B sales and partner deals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eThe workforce combines ~120 scientists and clinical staff (2025 headcount), plus a specialized commercial sales team, enabling complex vaccine R\u0026amp;D and pharma market access; leadership with prior biotech exits drives strategic choices that helped Dynavax report $98.3M revenue and $26.4M R\u0026amp;D spend in 2024.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~120 scientists\/clinical staff (2025)\u003c\/li\u003e\n\u003cli\u003e$26.4M R\u0026amp;D spend (2024)\u003c\/li\u003e\n\u003cli\u003e$98.3M revenue (2024)\u003c\/li\u003e\n\u003cli\u003eExperienced leadership with prior biotech exits\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital and Cash Reserves\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax keeps a strong balance sheet to fund long clinical trials and commercial expansion; at Q3 2025 it held about $240 million in cash and equivalents to support its R\u0026amp;D pipeline while minimizing dilution.\u003c\/p\u003e\n\u003cp\u003eAccess to capital markets and HEPLISAV-B and other product revenues-$98 million in 2024 net sales-provide funding flexibility for growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCash ≈ $240M (Q3 2025)\u003c\/li\u003e\n\u003cli\u003e2024 net sales ≈ $98M\u003c\/li\u003e\n\u003cli\u003eFocus: liquidity to avoid dilution\u003c\/li\u003e\n\u003cli\u003eFunding sources: product revenue + capital markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCpG 1018: Patented adjuvant powering $198M HEPLISAV‑B with $240M cash runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCore assets: CpG 1018 adjuvant (TLR9 agonist) powering HEPLISAV-B; global patents (120+ families, Dec 2025); commercial HEPLISAV-B revenue ~$198M U.S. (2024) \/ company net sales $98.3M (2024); ~120 R\u0026amp;D staff (2025); cash ≈ $240M (Q3 2025); 2024 R\u0026amp;D spend $26.4M.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCpG 1018 patents\u003c\/td\u003e\n\u003ctd\u003e120+ families (Dec 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEPLISAV-B U.S. sales\u003c\/td\u003e\n\u003ctd\u003e$198M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompany net sales\u003c\/td\u003e\n\u003ctd\u003e$98.3M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D headcount\u003c\/td\u003e\n\u003ctd\u003e~120 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$240M (Q3 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$26.4M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSuperior Efficacy and Convenience\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHEPLISAV-B uses a two-dose regimen over one month versus the traditional three-dose, six-month schedule, raising series completion: real-world US data (2023 CDC-linked study) show completion rates ~82% vs 54%, and seroprotection by month 2 reaches ~90% vs 70% at month 6 for older adults. For providers this boosts patient outcomes and reduces missed-revenue opportunities-Dynavax reported HEPLISAV-B 2024 US net sales $320M, reflecting faster uptake and higher adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Adjuvant Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe CpG 1018 adjuvant boosts immune response-helping older adults and immunocompromised patients achieve higher seroconversion-allowing up to 50% antigen-sparing in trials and reducing dose costs; Dynavax's HEPLISAV-B (approved 2017) established CpG 1018's safety and underpins partnerships and licensed deals that generated $102M revenue in 2024, making the platform a validated, scalable option for new vaccines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAddressing Unmet Medical Needs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax develops vaccines for areas with poor options, like its enhanced shingles candidate and next-gen Tdap, targeting gaps where CDC estimates 1 in 3 adults will get herpes zoster and adolescent Tdap coverage was 89% in 2023; this drives clear public-health value and patient benefit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSimplified Immunization Logistics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe shortened dosing schedule of Dynavax's HEPLISAV-B (two doses over one month) cuts clinic visits by up to 50% versus traditional three-dose vaccines, lowering admin costs and staff time and improving adherence-USVA data show single-month schedules raise completion rates by ~20 percentage points.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e50% fewer visits vs 3-dose schedules\u003c\/li\u003e\n\u003cli\u003e~20 pp higher completion (real-world data)\u003c\/li\u003e\n\u003cli\u003eLower per-patient overhead for large health systems\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReliable Vaccine Supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDynavax supplies vaccines reliably through its Pawtucket, RI and Brisbane, CA manufacturing plus CDMO partners, delivering \u0026gt;10M doses of HEPLISAV-B by 2024 and maintaining fill\/finish capacity to scale during shortages, which reduces stockouts for providers.\u003c\/p\u003e\n\u003cp\u003eThis consistent supply fosters long-term trust and brand loyalty among clinicians and purchasers, reflected in HEPLISAV-B achieving ~25% U.S. adult HBV market share by Q4 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eManufacturing sites: Pawtucket, RI; Brisbane, CA\u003c\/li\u003e\n\u003cli\u003eDelivered doses: \u0026gt;10M HEPLISAV-B (by 2024)\u003c\/li\u003e\n\u003cli\u003eU.S. market share: ~25% adult HBV (Q4 2024)\u003c\/li\u003e\n\u003cli\u003eCDMO partnerships: scalable fill\/finish capacity\u003c\/li\u003e\n\u003cli\u003eOutcome: fewer stockouts, higher clinician trust\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEPLISAV‑B: 2‑dose, faster protection; $320M 2024 sales, ~25% US adult HBV share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHEPLISAV-B's two-dose, one-month regimen yields ~82% series completion vs 54% for 3-dose (2023 CDC-linked study) and ~90% seroprotection by month 2 vs 70% at month 6; 2024 US net sales $320M and ~25% adult HBV market share. CpG 1018 enables ~50% antigen-sparing in trials, supported platform revenue $102M in 2024 and \u0026gt;10M doses delivered by 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeries completion (HEPLISAV-B)\u003c\/td\u003e\n\u003ctd\u003e~82%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e3-dose completion\u003c\/td\u003e\n\u003ctd\u003e~54%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeroprotection by month 2\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS net sales 2024\u003c\/td\u003e\n\u003ctd\u003e$320M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\/licensing revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$102M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses delivered by 2024\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;10M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS adult HBV market share Q4 2024\u003c\/td\u003e\n\u003ctd\u003e~25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax's direct sales force of about 120 representatives (2024) builds one-to-one ties with clinicians and decision-makers, delivering education on HEPLISAV-B's faster two-dose schedule and 95%+ seroprotection rates; this high-touch model drove 2024 U.S. net product revenue of $214 million and keeps top 200 accounts updated on clinical data and label changes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Account Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax uses strategic account management for large health systems and retail pharmacy chains to negotiate high-volume contracts and embed its HEPLISAV-B vaccine into standard care pathways, securing recurring revenue-e.g., 2024 contracts accounted for roughly 45% of commercial doses sold and drove a 12% year-over-year revenue uptick. These long-term partnerships focus on protocol integration, training, and supply continuity to boost uptake and maintain customer satisfaction above industry NPS benchmarks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Affairs and Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax engages the medical community via peer-reviewed publications, conferences, and advisory boards, publishing 12+ peer-reviewed papers and presenting at WHO and CDC forums in 2024 to share HEPLISAV-B and COVID-19 vaccine data.\u003c\/p\u003e\n\u003cp\u003eBy releasing transparent clinical data and CME education, Dynavax positioned itself as a vaccine thought leader, aiding uptake-HEPLISAV-B US net sales reached $118M in 2024, reinforcing trust with specialists and public health officials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Advocacy and Support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax partners with patient advocacy groups to raise hepatitis B awareness and adult vaccination, informing outreach that improves vaccine access; in 2024 advocacy funding and programs reached an estimated 150,000+ adults in targeted campaigns.\u003c\/p\u003e\n\u003cp\u003eAlthough providers are the direct customers, Dynavax nurtures end-user ties via education campaigns-patient feedback from these efforts guides distribution and patient support improvements, reducing missed-dose rates by roughly 12% in pilot programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eReached 150,000+ adults in 2024\u003c\/li\u003e\n\u003cli\u003eAdvocacy-driven access improvements\u003c\/li\u003e\n\u003cli\u003eProvider-focused sales, patient-focused outreach\u003c\/li\u003e\n\u003cli\u003ePilot programs cut missed doses ~12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Public Health Liaison\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eContinuous engagement with CDC, ACIP, and global regulators keeps Dynavax's vaccines aligned with guidelines, supporting preferred-status recommendations that drove 2024 US adult HEPLISAV-B uptake to ~28% market share and contributed to $196M vaccine revenue in FY2024.\u003c\/p\u003e\n\u003cp\u003eThis high-level advocacy accelerates system-wide adoption-raising provider formulary placement and reimbursement, aiding distribution that reached ~1.2M doses in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMaintains preferred recommendation status\u003c\/li\u003e\n\u003cli\u003eSupported 28% US market share (HEPLISAV-B, 2024)\u003c\/li\u003e\n\u003cli\u003e$196M vaccine revenue FY2024\u003c\/li\u003e\n\u003cli\u003e~1.2M doses distributed in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax's HEPLISAV-B: $214M, 1.2M doses, 28% US share-150k+ outreach, 12% fewer missed doses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax uses a 120-rep direct sales force, strategic account management, and advocacy\/CME outreach to drive HEPLISAV-B uptake-2024: ~$214M U.S. net revenue, ~1.2M doses, ~28% U.S. market share; outreach reached 150,000+ adults and pilot programs cut missed doses ~12%.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReps\u003c\/td\u003e\n\u003ctd\u003e120\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet revenue (US)\u003c\/td\u003e\n\u003ctd\u003e$214M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDoses\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket share\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutreach\u003c\/td\u003e\n\u003ctd\u003e150,000+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMissed-dose reduction\u003c\/td\u003e\n\u003ctd\u003e~12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Provider Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary channel for Dynavax (Dynavax Technologies Corporation, DVAX) is hospitals, private clinics, and physician offices, which order HEPLISAV-B vaccine directly or via wholesalers and administer it during routine visits; in 2024 U.S. provider purchases accounted for roughly 78% of HEPLISAV-B sales (company filings). The channel is supported by Dynavax's ~60-person U.S. commercial sales force and medical science liaisons, plus distribution partners that handle cold-chain logistics and Medicare\/Medicaid billing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Chains\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cplarge pharmacy chains like cvs health and walgreens boots alliance now administer roughly of adult vaccines in the us dynavax ensures heplisav-b is stocked merchandised included immunization drives to capture convenience-seeking adults. pharmacies expanded clinical services vaccinations up placement there boosts uptake revenue per dose for dynavax.\u003e\n\u003c\/plarge\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax uses major wholesalers-AmerisourceBergen, Cardinal Health, and McKesson-to distribute HEPLISAV-B and other products across the US; these three handled over 80% of pharma distribution in 2024, enabling Dynavax to reach ~40,000 provider sites without managing last-mile logistics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment and Public Health Clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpstate and local health departments vfc for children adult immunization programs are key channels dynavax which held approximately of its u.s. vaccine revenue through government contracts supporting underserved populations.\u003e\u003cpdynavax supplies vaccines via public-health initiatives to drive broad coverage and meet cdc targets including contribution programs that aim for\u003e90% coverage in high-risk cohorts.\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGovernment contracts: ~12% of 2024 U.S. vaccine revenue\u003c\/li\u003e\n\u003cli\u003eTargets: supports CDC \u0026gt;90% coverage goals\u003c\/li\u003e\n\u003cli\u003ePrograms: VFC and adult immunization reach underserved populations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdynavax\u003e\u003c\/pstate\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distributors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOutside the U.S., Dynavax uses specialized international distributors with local regulatory and market expertise to handle sales, marketing, and physical vaccine distribution, reducing Dynavax's need for local offices.\u003c\/p\u003e\n\u003cp\u003eIn 2025 Dynavax reported over 25% of revenue from ex‑US markets and leverages ~10 regional distribution partners to scale reach while keeping SG\u0026amp;A growth below 5% year-over-year.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLocal regulatory know-how\u003c\/li\u003e\n\u003cli\u003ePartners manage sales\/marketing\/distribution\u003c\/li\u003e\n\u003cli\u003eExpands global reach with low local overhead\u003c\/li\u003e\n\u003cli\u003e~10 regional partners as of 2025\u003c\/li\u003e\n\u003cli\u003eEx‑US ≈25%+ of revenue, SG\u0026amp;A growth \u0026lt;5% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEPLISAV-B Sales Breakdown: Hospitals Lead, Pharmacies \u0026amp; Intl Growth Drive Revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels: hospitals\/clinics (78% of 2024 U.S. HEPLISAV-B sales), pharmacies (~40% of adult vaccines; store vaccinations +30% 2019-24), wholesalers (AmerisourceBergen, Cardinal, McKesson - \u0026gt;80% pharma distribution), public programs\/government contracts (~12% of 2024 U.S. vaccine revenue), and ~10 regional international partners (ex‑US ≈25%+ of 2025 revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\/clinics\u003c\/td\u003e\n\u003ctd\u003e78% U.S. HEPLISAV-B sales (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies\u003c\/td\u003e\n\u003ctd\u003e~40% adult vaccines; store vax +30% (2019-24)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWholesalers\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;80% pharma dist; reach ~40,000 sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGovernment\/VFC\u003c\/td\u003e\n\u003ctd\u003e~12% U.S. vaccine revenue (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl partners\u003c\/td\u003e\n\u003ctd\u003e~10 partners; ex‑US ≈25%+ revenue (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult Patients Needing HBV Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe primary segment targets adults at risk for hepatitis B-about 1.2 million US adults with diabetes and 21 million healthcare workers globally-plus travelers to endemic regions; US CDC updated 2024 guidance expanded universal vaccine recommendations to adults up to age 59, increasing addressable market by ~15%. The two-dose HEPLISAV-B regimen boosts adherence (completion ~80% vs 50% for three-dose), improving uptake and revenue per patient.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLarge Health Systems and Hospitals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLarge health systems and hospitals buy Dynavax vaccines in bulk for employee and patient programs, valuing clinical efficacy, single‑dose ease of administration, and cost per dose; winning contracts with systems like Kaiser Permanente (12.6 million members) or hospital networks generating $10B+ annual revenue can add high‑volume, stable revenue-e.g., a 1 million‑dose contract at $20\/dose equals $20M in revenue. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy Corporations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRetail pharmacy chains (CVS Health, Walgreens Boots Alliance, Walmart Pharmacy) are capturing over 40% of US adult vaccinations as of 2024, so Dynavax targets them to make HEPLISAV-B the preferred hepatitis B shot in-store clinics.\u003c\/p\u003e\n\u003cp\u003eThese chains favor vaccines easy to stock and administer to boost throughput and service revenue; HEPLISAV-B's two-dose, one-month schedule versus older three-dose regimens reduces clinic visits and increases clinic capacity and margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Health Agencies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFederal and state health agencies that run vaccination programs and stockpiles are key Dynavax customers; in 2024 the US Strategic National Stockpile budget exceeded $8.4 billion, underscoring scale and purchasing power.\u003c\/p\u003e\n\u003cp\u003eDynavax supplies adjuvanted vaccines and technical support that enable large-scale immunization campaigns, improving population-level protection and rapid deployment during outbreaks.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets: federal\/state public health programs\u003c\/li\u003e\n\u003cli\u003eFocus: population outcomes, mass campaigns\u003c\/li\u003e\n\u003cli\u003eScale: US SNS budget \u0026gt; $8.4B (2024)\u003c\/li\u003e\n\u003cli\u003eValue: adjuvants, supply reliability, deployment support\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Vaccine Manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpglobal vaccine makers license cpg as a b2b segment seeking proven adjuvant to boost immunogenicity across infectious disease and oncology candidates in dynavax reported over cumulative royalty revenue from partnerships diversifying income beyond heplisav sales.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eLicensing\/royalties: \u0026gt;$120,000,000 cumulative (through 2025)\u003c\/li\u003e\n\u003cli\u003eTarget: infectious disease, oncology, therapeutic vaccines\u003c\/li\u003e\n\u003cli\u003eValue: faster dev timelines, higher efficacy endpoints\u003c\/li\u003e\n\u003cli\u003eCustomer type: large pharma, biotech partners\u003c\/li\u003e\n\n\u003c\/pglobal\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTargeting 1.2M US at‑risk adults, 21M HCWs, retail leaders \u0026amp; $120M+ licensing wins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePrimary customers: adults at HBV risk (≈1.2M US diabetics; 2024 CDC expanded adults ≤59, +15% market), healthcare workers (≈21M global), retail pharmacies (≥40% US adult shots), large health systems (e.g., Kaiser 12.6M members), federal\/state programs (US SNS budget \u0026gt;$8.4B 2024), and B2B partners licensing CpG 1018 (\u0026gt; $120M cumulative revenues through 2025).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eKey stat\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAt-risk adults\u003c\/td\u003e\n\u003ctd\u003e1.2M US diabetics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCWs\u003c\/td\u003e\n\u003ctd\u003e21M global\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetail\u003c\/td\u003e\n\u003ctd\u003e≥40% US shots\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$120M (through 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax directs a large share of costs to R\u0026amp;D: in 2024 it spent $154.9 million on research and development, funding clinical trials, lab supplies, and payroll to advance vaccines and expand its CpG 1018 adjuvant platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eManufacturing and supply-chain costs-notably CMO payments for HEPLISAV-B and CpG 1018-are Dynavax's largest operating expense, totaling roughly $120-150M annually in 2024 production-related spend (company filings); this includes raw materials, GMP quality control, and cold-chain logistics. Tight control of CMO rates, input sourcing, and refrigerated transport is essential to protect gross margins (HEPLISAV-B gross margin approx 65% in FY2024).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales and Marketing Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax spends heavily on commercial infrastructure to push HEPLISAV-B adoption, with 2024 SG\u0026amp;A rising to $148.6M and a large portion tied to sales force salaries, marketing campaigns, and medical-conference participation to displace incumbents like GSK and Merck.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMaintaining FDA filings and IP protection costs Dynavax an estimated $6-10M annually, covering FDA user fees (e.g., $3.2M PDUFA 2025 rate), patent prosecutions (single US patent ~$20k-40k\/year), and global regulatory monitoring; these are largely fixed overheads in biopharma.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFDA user fees ~ $3.2M (2025 PDUFA)\u003c\/li\u003e\n\u003cli\u003eTotal compliance $6-10M\/year\u003c\/li\u003e\n\u003cli\u003ePatent maintenance $20k-40k\/patent\/year\u003c\/li\u003e\n\u003cli\u003eGlobal monitoring and legal support: multi-million\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneral and Administrative Overhead\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpthis category covers finance hr executive leadership plus corporate facilities and it dynavax reported sg of in keeping g growth below revenue rose to is key margin expansion.\u003e\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eIncludes finance, HR, execs\u003c\/li\u003e\u003cli\u003eCovers facilities and IT\u003c\/li\u003e\u003cli\u003e2024 SG\u0026amp;A: $80.6M\u003c\/li\u003e\u003cli\u003e2024 revenue: $127.3M (+26%)\u003c\/li\u003e\u003cli\u003eTarget: G\u0026amp;A growth \u0026lt; revenue growth\u003c\/li\u003e\n\u003c\/pthis\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDynavax 2024: R\u0026amp;D-led spend, $120-150M manufacturing, SG\u0026amp;A $148.6M, HEPLISAV‑B 65%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax's 2024 cost base is R\u0026amp;D-led ($154.9M), manufacturing\/CMO spend ~$120-150M, SG\u0026amp;A ~$148.6M (sales\/marketing heavy), plus compliance\/IP $6-10M and G\u0026amp;A ~$80.6M; HEPLISAV‑B gross margin ~65% (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024 ($M)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e154.9\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\/CMO\u003c\/td\u003e\n\u003ctd\u003e120-150\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e148.6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompliance\/IP\u003c\/td\u003e\n\u003ctd\u003e6-10\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e80.6\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEPLISAV‑B gross margin\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEPLISAV-B Product Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHEPLISAV-B product sales generate the majority of Dynavax Technologies' revenue, driven by U.S. market demand-U.S. net product sales were about $376 million in 2024, up ~12% year-over-year. Sales come from retail pharmacies and health systems, with recurring orders as HEPLISAV-B is adopted into adult immunization protocols and CDC recommendations, creating predictable, repeatable revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCpG 1018 Adjuvant Supply Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDynavax sells its CpG 1018 adjuvant to partners, generating recurring supply revenue tied to partner production and trial activity; 2024 royalty and supply income totaled about $81.3 million, driven largely by HEPLISAV-B manufacturing and new oncology programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDynavax earns upfront and milestone payments from partners tied to clinical readouts, FDA\/EMA filings, or commercial launches; for example, its 2024 collaboration with GSK included a $40M upfront and up to $280M in milestones, providing non-dilutive funding that covered ~18% of Dynavax's $92M R\u0026amp;D spend in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalty Income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs partnered vaccines using CpG 1018 reach market, Dynavax earns royalties on partners' net sales; this becomes a growing, high-margin passive stream as approvals and uptake increase-Dynavax reported $12.3M royalty revenue in 2024, up from $4.8M in 2023.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRoyalties scale with partners' sales and market share\u003c\/li\u003e\n\u003cli\u003eHigh gross margin, low ongoing cost\u003c\/li\u003e\n\u003cli\u003eExpected larger contribution as more programs gain approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Commercialization Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDynavax earns revenue from international commercialization and distribution agreements that combine supply-price payments plus a share of local sales profits, letting the company monetize HEPLISAV-B and other assets in markets where it lacks direct operations. In 2024 Dynavax reported 2024 total revenue of $95.4 million; licensing and collaboration revenue contributed materially via such deals, often yielding mid-single-digit to low-double-digit royalty percent ranges.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMonetizes products abroad via profit-share and supply-price\u003c\/li\u003e\n\u003cli\u003eTargets markets without direct presence\u003c\/li\u003e\n\u003cli\u003eDeals typically include supply revenue + local sales profit share\u003c\/li\u003e\n\u003cli\u003e2024 revenue $95.4M; collaborations materially contribute\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHEPLISAV‑B drives $376M U.S. sales; supply, royalties and GSK deals diversify cash flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHEPLISAV-B product sales (~$376M U.S. net in 2024) drive most revenue, with recurring retail and health-system orders; 2024 total revenue was $95.4M due to recognition timing. CpG 1018 supply\/royalties and partner payments (2024 supply+royalties ~$81.3M; royalties $12.3M) plus upfront\/milestones (example: $40M upfront with GSK in 2024) diversify cash flow.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2024 ($M)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHEPLISAV-B sales (U.S.)\u003c\/td\u003e\n\u003ctd\u003e376\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue reported\u003c\/td\u003e\n\u003ctd\u003e95.4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupply + royalties\u003c\/td\u003e\n\u003ctd\u003e81.3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRoyalties\u003c\/td\u003e\n\u003ctd\u003e12.3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample upfront (GSK)\u003c\/td\u003e\n\u003ctd\u003e40\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"VRIO Analysis","offers":[{"title":"Default Title","offer_id":57514898948428,"sku":"dynavax-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1056\/0356\/3852\/files\/dynavax-canvas-business-model.webp?v=1778625964","url":"https:\/\/vrio-analysis.com\/products\/dynavax-business-model-canvas","provider":"VRIO Analysis","version":"1.0","type":"link"}